Cue Biopharma(US:CUE) Globenewswire·2026-03-09 12:00Core Viewpoint - Cue Biopharma, Inc. is advancing its lead asset CUE-401, a novel bifunctional therapeutic designed to treat autoimmune and inflammatory diseases, with a poster presentation scheduled at the World Immune Regulation Meeting in March 2026, showcasing new in vitro data that supports its therapeutic potential [1][2]. Group 1: CUE-401 Presentation Details - The poster presentation will be held on March 12, 2026, by Natasha M. Girgis, Director of Translational Pharmacology, focusing on CUE-401's ability to inhibit proinflammatory immune cells through TGF-beta [2]. - The session is categorized under Autoimmunity and Innate Immunity, highlighting the significance of CUE-401 in addressing autoimmune conditions [2]. Group 2: Mechanism of Action - CUE-401 operates through three mechanisms: direct regulation of proinflammatory pathways via TGF-beta, expansion of regulatory T cells (Tregs) through IL-2, and conversion of conventional CD4+ T cells into FOXP3+ induced Tregs [4]. - The therapeutic effects of CUE-401 include suppression of proinflammatory cytokines in CD4+ T effector memory cells and prevention of activated B cells from differentiating into plasma cells, thereby limiting antibody production [3]. Group 3: Company Overview - Cue Biopharma is a clinical-stage biopharmaceutical company focused on developing injectable biologics that selectively engage and modulate disease-specific T cells, aiming to harness the body's immune system without broad systemic effects [5]. - The company utilizes its proprietary Immuno-STAT® platform to create therapeutics like CUE-401, which is designed to act as a master switch for Treg differentiation and immune tolerance [5].